Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coal tar safety

This article was originally published in The Tan Sheet

Executive Summary

FDA asked to conduct "formal review" of coal tar use in shampoo, soap and ointments by Occupational Knowledge International in a March 6 petition. The agency should "restrict the sales and distribution of these products to prescription sales," the group states. As a "known carcinogen...labeling requirements are insufficient and require additional warning to protect public health." Coal tar, which appears in Whitehall-Robins' Denorex and Block Drug's Tegrin, was banned from use in OTC drug products by Germany in 1995 and the EU in 1997, the comments point out
Advertisement

Related Content

Coal tar
Coal tar
Coal Tar Dandruff Shampoo Cancer Risk Negligible, Whitehall Data Indicate
Coal Tar Dandruff Shampoo Cancer Risk Negligible, Whitehall Data Indicate
Coal Tar Dandruff Shampoo Cancer Risk Negligible, Whitehall Data Indicate
California Coal Tar Litigation Stay Sought Pending FDA Petition Review
California Coal Tar Litigation Stay Sought Pending FDA Petition Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS091030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel